Are you a start-up, small business or established company developing medical technologies to improve patient outcomes and reduce costs to the NHS? You may have identified a real day-to-day problem, and developed a great product to address it, but without clinical evidence obtained within our health system, it’s impossible to demonstrate the value of your proposition. And without evidence, NHS buyers and NICE have nothing to evaluate, so progress is stalled. Sound familiar?
In response to this need, Wessex Academic Health Science Network (AHSN) and Wessex Clinical Research Network (CRN) have joined forces to create a new Technology Support Programme (TSP) which will help commercial innovators gather NHS evidence on their products, and help get effective innovations to patients faster.
The TSP is a package of strategic and clinical support for companies wanting to gather evidence on the clinical and economic efficacy of their product within the NHS and medical technology companies are now invited to apply for places on the programme.
A targeted theme will be chosen for each of the TSP rounds.
The TSP is in four parts:
The TSP (Round 1) Theme is: Innovative Rapid Diagnostic Testing and Point-of-Care Testing for Infectious Diseases
Diagnostic testing for infectious diseases has traditionally used tests of moderate or high complexity delivered in centralised microbiology laboratories by highly trained staff. This approach is associated with turnaround times of several days for generating results to clinicians, and means that clinical decisions, including antimicrobial use, have to be made presumptively. This leads to the over use of antibiotics which subsequently drives the development of antimicrobial resistance.
Rapid diagnostic tests and Point-of-Care tests for infection allow testing to take place outside of the laboratory, at or near the patient, and enable real-time clinical decision making. Potential benefits of this approach include improved use of antimicrobial agents and improved clinical outcomes. In addition to detecting pathogen themselves, the rapid detection of serum biomarkers or host gene signatures that can accurately differentiate bacterial from non-bacterial infection may also allow reduction in unnecessary antibiotic prescribing in primary and secondary care. These types of innovative technology are therefore of great interest to the NHS.
TSP (Round 1) is seeking companies that are working in this area and have an innovation, not currently in use in the NHS, which they want to evaluate in an NHS setting.
How to apply: